Theriva Biologics, Inc. (TOVX)

ASE – Цена в реальном времени. Валюта: USD

0.25

+0.01 (4.52%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

0.24

-0.01 (-3.84%)

После закрытия: Jun 26, 2026, 7:55 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Theriva Biologics, Inc. (TOVX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Theriva Biologics, Inc. (TOVX)

Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research

Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results

Why Is Theriva Stock Gaining Monday?

Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting

Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Theriva Biologics Provides Response to Unusual Market Action

Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results

Видео

No Data

Пресс-релизы

Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research

Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results

Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting

Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Search stocks

Theriva Biologics, Inc. (TOVX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Theriva Biologics, Inc. (TOVX)

Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research

Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results

Why Is Theriva Stock Gaining Monday?

Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting

Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Theriva Biologics Provides Response to Unusual Market Action

Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results

Видео

No Data

Пресс-релизы

Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research

Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results

Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting

Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)